| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 25.667 | 43.600 | 52.384 | 145.465 | 291.847 | 271.693 | 154.363 | 182.527 | 225.975 | 342.062 |
| Total Income - EUR | 26.686 | 45.305 | 52.940 | 147.662 | 293.696 | 273.870 | 154.381 | 188.243 | 240.794 | 345.775 |
| Total Expenses - EUR | 21.100 | 34.585 | 41.341 | 128.376 | 245.952 | 228.008 | 152.125 | 173.964 | 204.000 | 288.243 |
| Gross Profit/Loss - EUR | 5.585 | 10.720 | 11.600 | 19.285 | 47.743 | 45.862 | 2.256 | 14.279 | 36.794 | 57.532 |
| Net Profit/Loss - EUR | 4.785 | 9.361 | 10.288 | 17.812 | 45.250 | 43.388 | 713 | 12.397 | 34.491 | 48.715 |
| Employees | 0 | 0 | 1 | 2 | 3 | 2 | 2 | 1 | 2 | 3 |
Check the financial reports for the company - Tuvet Pharm S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 248 | 4.422 | 11.224 | 32.050 | 20.034 | 13.828 | 6.376 | 3.285 | 8.028 |
| Current Assets | 16.162 | 27.592 | 35.486 | 55.519 | 92.381 | 45.234 | 77.695 | 82.478 | 128.336 | 172.241 |
| Inventories | 7.987 | 15.183 | 18.621 | 30.102 | 32.694 | 17.330 | 43.847 | 38.353 | 41.575 | 56.404 |
| Receivables | 6.172 | 10.695 | 7.079 | 13.839 | 29.353 | 12.392 | 28.376 | 28.880 | 41.408 | 59.253 |
| Cash | 2.003 | 1.715 | 9.786 | 11.579 | 30.333 | 15.512 | 5.473 | 15.245 | 45.354 | 56.584 |
| Shareholders Funds | 11.281 | 20.527 | 30.467 | 47.720 | 86.988 | 43.430 | 43.179 | 55.710 | 90.033 | 133.874 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 5.047 | 7.477 | 9.602 | 19.478 | 38.790 | 23.311 | 49.797 | 34.495 | 42.936 | 47.735 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4646 - 4646" | |||||||||
| CAEN Financial Year |
4646
|
|||||||||
Comments - Tuvet Pharm S.r.l.